BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed S, Ellis M, Li H, Pallucchini L, Stein AM. Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems. J Pharmacokinet Pharmacodyn 2019;46:287-304. [PMID: 31037615 DOI: 10.1007/s10928-019-09638-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer 2022;10:e003776. [PMID: 35217575 DOI: 10.1136/jitc-2021-003776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Reference Citation Analysis]
3 Tang Y, Li X, Cao Y. Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discov Today 2021;26:1980-90. [PMID: 33895315 DOI: 10.1016/j.drudis.2021.04.022] [Reference Citation Analysis]
4 Alaybeyoglu B, Cheng HWJ, Doshi KA, Makani V, Stein AM. Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included. J Pharmacokinet Pharmacodyn 2021;48:447-64. [PMID: 33558979 DOI: 10.1007/s10928-020-09734-9] [Reference Citation Analysis]
5 Menezes B, Cilliers C, Wessler T, Thurber GM, Linderman JJ. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens. AAPS J 2020;22:29. [PMID: 31942650 DOI: 10.1208/s12248-019-0391-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Irurzun-Arana I, Rackauckas C, McDonald TO, Trocóniz IF. Beyond Deterministic Models in Drug Discovery and Development. Trends Pharmacol Sci 2020;41:882-95. [PMID: 33032836 DOI: 10.1016/j.tips.2020.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]